An FDA advisory panel backed Grail’s Galleri multi-cancer blood test, boosting investor confidence and sending shares past Wall Street’s average price target, nearly doubling in the past month. However, the test’s ability to detect cancer early remains unproven, with a U.K. trial showing it identified only 14% of Stage 1 cancers versus 60% at Stage 4, and failed to reduce late-stage cancers overall. While the FDA is expected to approve the test, its broader impact hinges on whether insurers, particularly Medicare, will cover it.
A 2023 law creates a pathway for Medicare coverage starting in 2029, but payment is not guaranteed, as the Centers for Medicare and Medicaid Services must determine if the test is reasonable and necessary. Analysts note Grail’s stock is priced for near-certain coverage, though experts see odds closer to a coin flip. A favorable ruling may come with conditions like 'coverage with evidence development,' delaying broad adoption.
Even if approved, coverage would begin slowly, limited initially to ages 50–65, expanding gradually.
Source: Wall Street Journal Markets · Summarized by HeadlinesBriefing